---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-034544"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T21:55:12.953730+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abbott Q3 adj EPS $1.14, rev $10.1B; raises FY23 EPS midpoint

## Summary
- Q3 GAAP EPS $0.82; adjusted EPS $1.14; reported sales $10.1B (-2.6% YoY).
- Organic base-business sales (ex-COVID tests) up 13.8%; double-digit growth in all four segments.
- Full-year 2023 adjusted EPS guidance raised to $4.42–$4.46 (midpoint $4.44 vs prior $4.30–$4.50).
- Medical Devices organic growth 14.7%; FreeStyle Libre sales $1.4B (+28.5% organic).
- Quarterly dividend maintained at $0.51/share; 399th consecutive quarterly payout.

## SEC filing metadata
- accession: 0001628280-23-034544
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828023034544/0001628280-23-034544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828023034544/abt-20231018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-034544
- JSON: https://secwatch.observer/filing/0001628280-23-034544.json
- Plain text: https://secwatch.observer/filing/0001628280-23-034544.txt

## Key facts
- Earnings Releases
  ABBOTT LABORATORIES updated its third quarter ended Sept. 30, 2023 guidance (raised).
  - Period: third quarter ended Sept. 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: Abbott today announced financial results for the third quarter ended Sept. 30, 2023. • Third-quarter GAAP diluted EPS of $0.82 and adjusted diluted EPS of $1.14, which excludes specified items. • Abbott narrowed its full-year 2023 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.14 to $3.18 and projects adjusted diluted EPS of $4.42 to $4.46, which represents an increase at the midpoint of the guidance range.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000162828023034544/0001628280-23-034544-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.